Bristol-Myers Squibb Company (BMY)vsTotalEnergies SE ADR (TTE)
BMY
Bristol-Myers Squibb Company
$57.27
+1.18%
HEALTHCARE · Cap: $114.19B
TTE
TotalEnergies SE ADR
$89.40
+0.78%
ENERGY · Cap: $195.51B
Smart Verdict
WallStSmart Research — data-driven comparison
TotalEnergies SE ADR generates 279% more annual revenue ($183.96B vs $48.48B). BMY leads profitability with a 15.0% profit margin vs 8.2%. TTE appears more attractively valued with a PEG of 0.72. TTE earns a higher WallStSmart Score of 72/100 (B).
BMY
Buy60
out of 100
Grade: C+
TTE
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+17.2%
Fair Value
$72.40
Current Price
$57.27
$15.13 discount
Intrinsic value data unavailable for TTE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 36 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Earnings expanding 57.1% YoY
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.3%
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
3.4% revenue growth
Grey zone — moderate risk
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : TTE
The strongest argument for TTE centers on EPS Growth, Market Cap, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.22 is elevated, increasing financial risk.
Bear Case : TTE
The primary concerns for TTE are Revenue Growth, Altman Z-Score, Piotroski F-Score.
Key Dynamics to Monitor
BMY carries more volatility with a beta of 0.24 — expect wider price swings.
TTE is growing revenue faster at 3.4% — sustainability is the question.
BMY generates stronger free cash flow (757M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TTE scores higher overall (72/100 vs 60/100). BMY offers better value entry with a 17.2% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →TotalEnergies SE ADR
ENERGY · OIL & GAS INTEGRATED · USA
TotalEnergies SE is a global integrated oil and gas company. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?